Department of Surgery, Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School and Shriners Hospitals for Children, Boston, MA 02114, USA.
Cell Transplant. 2010;19(6):823-30. doi: 10.3727/096368910X508942. Epub 2010 Jun 23.
Bone marrow mesenchymal stromal cells (MSCs) suppress immune cell responses and have beneficial effects in various inflammatory-related immune disorders. A therapeutic modality for systemic inflammation and its consequences is not available yet. Thus, this work investigates the therapeutic effects of MSCs in injury models induced by lipopolysaccharide (LPS) or burn. Gene expression was analyzed in MSCs when exposed to inflammatory serum from injured animals and it showed remarkable alterations compared to normal culture. In addition, injured animals were transplanted intramuscularly with MSCs. Forty-eight hours after cell transplantation, kidney, lung, and liver were analyzed for infiltration of inflammatory cells and TUNEL-expressing cells. Results showed that MSCs attenuate injury by reducing the infiltration of inflammatory cells in various target organs and by reducing cell death. These data suggest that MSCs emerge as key regulators of immune/inflammatory responses in vivo and as attractive candidates for cell-based treatments for systemic inflammatory-based disorders.
骨髓间充质基质细胞(MSCs)抑制免疫细胞反应,并对各种炎症相关免疫紊乱具有有益作用。目前尚无针对全身炎症及其后果的治疗方法。因此,这项工作研究了 MSCs 在脂多糖(LPS)或烧伤诱导的损伤模型中的治疗效果。当 MSCs 暴露于来自受伤动物的炎症血清中时,分析了其基因表达,与正常培养相比,其显示出明显的改变。此外,受伤动物被肌肉内移植 MSCs。细胞移植后 48 小时,分析肾脏、肺和肝脏中炎症细胞和 TUNEL 表达细胞的浸润情况。结果表明,MSCs 通过减少各种靶器官中炎症细胞的浸润和减少细胞死亡来减轻损伤。这些数据表明,MSCs 作为体内免疫/炎症反应的关键调节剂出现,并作为基于细胞的治疗全身炎症性疾病的有吸引力的候选物。